PROXYGEN
Proxygen is a biotechnology firm specializing in protein degradation therapy for treatment of cancer and other life threatening dieseses.
PROXYGEN
Industry:
Biotechnology Life Science Therapeutics
Founded:
2020-01-01
Address:
Vienna, Wien, Austria
Country:
Austria
Website Url:
http://www.proxygen.com
Total Employee:
11+
Status:
Active
Contact:
+43 (0)1 226 1030
Email Addresses:
[email protected]
Total Funding:
0
Similar Organizations
Numab
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.
Investors List
Boehringer Ingelheim
Boehringer Ingelheim investment in Grant - Proxygen
Official Site Inspections
http://www.proxygen.com Semrush global rank: 8.56 M Semrush visits lastest month: 289
- Host name: shared-clump0039-web.agenturserver.it
- IP address: 185.237.67.198
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Proxygen"
Proxygen - Crunchbase Company Profile & Funding
Proxygen is reshaping the druggable space. Their company harnesses technology and know-how to exploit this potential, thereby redefining the …See details»
Proxygen - Hunters
Adam Davenport is Proxygen’s Chief Discovery Officer. A seasoned drug hunter and innovator, he brings over 24 years of hands-on life science and partnership organization experience, …See details»
Proxygen 2025 Company Profile: Valuation, Funding & Investors
Proxygen General Information Description. Developer of a novel drug discovery platform designed to identify glue degraders, small molecules designed to target specific proteins within a cell. …See details»
Proxygen - Funding, Financials, Valuation & Investors - Crunchbase
Proxygen is a biotechnology firm specializing in protein degradation therapy for treatment of cancer and other life threatening dieseses. New. Resources. ... How much funding has this …See details»
Proxygen - Overview, News & Similar companies | ZoomInfo.com
Apr 6, 2023 Proxygen Announces Collaboration and License Agreement with MSD for the Discovery and Development of Novel Molecular Glue Degraders VIENNA, Austria, April 05, …See details»
Proxygen GmbH - Drug pipelines, Patents, Clinical trials - Synapse
Mar 8, 2025 Proxygen announces a collaboration and licensing agreement with MSD for the discovery and development of novel molecular glue degraders On April 5, 2023, Proxygen, a …See details»
Proxygen - Crunchbase
Proxygen is a biotechnology firm specializing in protein degradation therapy for treatment of cancer and other life threatening dieseses. New. Resources. ... Log In. Experience the new …See details»
Proxygen GmbH - VentureRadar
Molecular glue degraders have been historically difficult to identify. At Proxygen, we have developed rational discovery assays that, for the first time, enable the identification and …See details»
Proxygen welcomes Adam Davenport as Chief …
Nov 26, 2024 Proxygen, a leader in the discovery and development of molecular glue degraders, today announced the appointment of Adam Davenport as Chief Discovery Officer. A seasoned drug hunter and innovator, Adam brings over …See details»
Proxygen Overview | SignalHire Company Profile
Organization Website: proxygen.com : Proxygen industries Biotech: Headquarters Location: Dr.-Bohr-Gasse 7, ... Biotech. To connect with Proxygen's employee register on Signalhire. Email …See details»
Proxygen GmbH - Life Sciences Directory
Proxygen harnesses the cellular protein quality control system to develop therapies against cancer and other life-threatening diseases. We are focused on particular small molecules …See details»
Proxygen Announces Formation of Board of Directors - Yahoo …
Mar 15, 2023 Accomplished Life Science Veterans with Broad Ranging Experience will Support Company’s Pioneering Work in the Discovery and Development of Novel Molecular Glue …See details»
Proxygen | CipherBio
Explore Proxygen's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
Chronicle - Proxygen
Mar 15, 2024 Proxygen announces collaboration and license agreement with MSD. 5 April 2023 — Proxygen, a leader in the discovery and development of molecular glue degraders, …See details»
Proxygen Announces Formation of Board of Directors
Mar 15, 2023 Proxygen is a leader in the discovery and development of molecular glue degraders against targets of unmet medical need across various indications. While advancing …See details»
Proxygen inks $2.5B deal with Merck & Co. as collabs stack up
Apr 5, 2023 Proxygen is adding another licensing deal to its repertoire, inking an agreement with Merck & Co. worth more than $2.5 billion. Proxygen’s molecular glue ambitions are continuing …See details»
Proxygen Announces Collaboration and License Agreement with …
VIENNA, Austria, April 05, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, announced today a multi-year research …See details»
Proxygen - Updates, News, Events, Signals & Triggers - Crunchbase
Proxygen is a biotechnology firm specializing in protein degradation therapy for treatment of cancer and other life threatening dieseses. Search Crunchbase. Start Free Trial . Chrome …See details»
Boehringer Ingelheim Collaborates with Proxygen | BI US
Ingelheim, Germany and Vienna, Austria, 7 December 2020 - Boehringer Ingelheim and Proxygen today announced they have entered into a collaboration and license agreement to enable the …See details»
Proxy Landscape – “The Times They are A-Changin”
5 days ago I. Overview As suggested by the musician Bob Dylan, in the Proxy field, the times are changing. This installment aims to address some of those changes and, perhaps more …See details»